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Summary 
 
The alarming rise of antibiotic resistant pathogens poses a serious threat to public health and 
urgently necessitates the development of new antibiotics. In order to reduce the selection pressure 
on bacteria, this study aims at the development of ‘pathoblockers’ which target bacterial virulence 
instead of killing the pathogens. In this context, secreted bacterial collagenases represent highly 
attractive targets because of their pivotal roles in the infection process and their advantageous 
extracellular localization. 
In this thesis, the development of inhibitors of ColH from Clostridium histolyticum and LasB from 
Pseudomonas aeruginosa is described. A class of N-aryl mercaptoacetamides displays promising 
activity on both targets, with distinct differences in structure-activity relationships and the binding 
mode to the respective protease. Synthetic efforts further led to the development of a hydroxamate 
derivative of the lead LasB inhibitor. 
The inhibitors described herein share a high selectivity toward mammalian matrix metalloproteases, 
which was rationalized by combining the information obtained from the co-crystal structures with 
computational approaches. Further biological assays shed light on the impact of LasB inhibition on 
key resistance mechanisms of P. aeruginosa and demonstrate in vivo efficacy in a Galleria 
mellonella infection model. 
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Zusammenfassung 
 
Der alarmierende Anstieg von Antibiotika-resistenten Bakterien stellt eine ernstzunehmende 
Bedrohung für die menschliche Gesundheit dar. Aus diesem Grund ist Entwicklung neuer 
Antibiotika dringend notwendig. Um den Selektionsdruck auf Bakterien zu reduzieren, hat diese 
Arbeit zum Ziel, „Pathoblocker“ zu entwickeln, welche die bakterielle Virulenz hemmen anstatt 
die Pathogene zu töten. In diesem Kontext stellen sezernierte bakterielle Kollagenasen sehr 
attraktive Targets dar, da sie eine zentrale Rolle im Infektionsprozess spielen und den Vorteil mit 
sich bringen, dass die bakterielle Zellwand nicht überwunden werden muss. 
In dieser Dissertation ist die Entwicklung von Inhibitoren der Enzyme ColH aus Clostridium 
histolyticum und LasB aus Pseudomonas aeruginosa beschrieben. Eine Klasse von 
N-Arylmercaptoacetamiden zeigt vielversprechende Aktivität an beiden Targets, allerdings mit 
klaren Unterschieden in den Struktur-Wirkungs-Beziehungen und im Bindungsmodus. Über 
chemische Synthese wurde weiterhin ein Hydroxamsäure-Derivat des besten LasB-Inhibitors 
entwickelt. 
Die hier beschriebenen Inhibitoren haben eine hohe Selektivität gegenüber humanen Matrix-
Metalloproteasen gemein, die über die Kristallstrukturen und Computer-basierte Methoden rational 
erklärt werden konnte. Weitere biologische Assays beleuchten die Auswirkung der LasB-
Hemmung auf zentrale Resistenzmechanismen von P. aeruginosa und zeigen in vivo-Effekte in 
einem Galleria mellonella-Infektionsmodell.  
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1 Introduction 
1.1 Proteases in Drug Discovery 
 
Proteases are enzymes capable of hydrolyzing peptide bonds.1 Based on the mechanism of 
hydrolysis, these enzymes are classified as serine, threonine or cysteine proteases, which covalently 
bind their substrates, and aspartic, glutamic or metalloproteases, which cleave peptides via non-
covalent catalysis involving an activated water molecule.1,2 Peptides are cleaved either at the N- or 
C-terminus (by exopeptidases) or in between (by endopeptidases).1,2 Conventionally, the amino 
acid residues of a substrate are labelled P1-Pn toward its N terminus and P1′-Pn′ toward the 
C terminus, starting from the scissile bond (Figure 1).3 Accordingly, the protease subsites which 
bind the respective amino acids are labelled S1-Sn (non-primed sites) and S1′-Sn′ (primed sites).3 
Based on their sequence homology, proteases are grouped into different families in a peptidase 
database named MEROPS.4 
 
 
 
Figure 1. Schematic overview of substrate cleavage sites and their respective binding sites at the surface of 
a protease. Non-primed binding sites are located toward the N terminus of the substrates (S1-Sn), primed 
binding sites toward the C terminus (S1′-Sn′). Adapted from Schechter and Berger3 
 
 
Proteases are important players in the regulation of human health and disease, since they control 
vital processes such as organ homeostasis, blood coagulation or tissue development, to name but a 
few.2,5,6 Consequently, their inhibition represents an attractive approach toward the treatment of 
various diseases.2,5,6  
A well-established method to develop protease inhibitors is to target the active site.6 Different 
strategies to obtain access to active site-directed ligands are nicely reflected in the history of the 
renin inhibitor aliskiren (Figure 2): the first peptidic inhibitors (e.g. H-142, 1) resembling the natural 
substrate angiotensinogen were modified to peptidomimetics serving as transition-state analogues 
(remikiren, 2).7 The idea of this approach is to generate an inhibitor which mimics the transition 
state of a substrate but binds with higher affinity and cannot be processed by the enzyme.8 In this 
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context, knowledge about the substrate specificity of a protease is of vital benefit, granting access 
to compounds resembling preferred amino acids at the cleavage site.6 In principle, this traces back 
to the lock and key model introduced by Fischer more than 120 years ago.9 In case of the bacterial 
zinc-metalloprotease thermolysin, transition-state analogues are represented by compounds bearing 
tetrahedral phosphonamidate functions with activity in the nano- to picomolar range.10 Since 
peptide-like inhibitors resemble protease substrates, resistance formation is believed to be reduced, 
because mutations would be disadvantageous when completely preventing the processing of natural 
substrates.11 
 
Figure 2. Schematic overview of the development cascade of renin inhibitors. Adapted from Drag, 
Salvesen6 and Jensen et al.7 
 
As an alternative to this ligand-based approach, structure-based methods have successfully been 
employed to discover specific protease inhibitors.2,5 These efforts can be based on virtual screening 
campaigns or on the screening of focused or fragment libraries,2,12 which can give rise to non-
peptidic inhibitors.5,6 A prominent example for a such an inhibitor is the approved drug aliskiren 
(3), which represents the latest step of the above mentioned development cascade for renin 
inhibitors.7 An advantage of such non-peptidic inhibitors is their insensitivity to inactivation by 
endogenous proteases, which can increase bioavailability.2 
With the aim of blocking the catalytic activity of a protease, it is well-established to equip inhibitors 
with so-called ‘warheads’ which directly interfere with the catalytic function of the enzyme.2,6 In 
case of covalent catalysis this can lead to irreversible inhibition (e.g. by epoxides), which is viewed 
critically because of the high potential of unwanted side-effects.2,13 In case of metalloprotease 
inhibition, compounds typically bear zinc-chelating moieties like thiols, hydroxamates or 
heterocycles.14 There has been a special focus on hydroxamic acids as MMP inhibitors for cancer 
therapy,15–19 which is outlined in more detail in chapter 1.6. 
Apart from addressing the catalytic unit of a protease, the activity can also be diminished by 
targeting allosteric binding sites, as with allosteric caspase inhibitors introduced by Hardy et al.20 
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This approach can prove useful for boosting selectivity, as conserved active sites are not targeted 
directly.6 
Several protease inhibitors are in clinical use (Figure 3), like ACE inhibitors for the reduction of 
blood pressure (e.g. captopril, 4),5 HDAC inhibitors for cancer treatment (e.g. vorinostat, 5),21 
thrombin inhibitors as antiplatelet drugs (e.g. argatroban, 6)5 or the previously highlighted anti-
hypertensive aliskiren (3, Figure 2).7 In contrast to these endogenous human proteases, the disease 
state in case of an infection is substantially regulated by exogenous bacterial or viral proteases, 
which are responsible for tissue invasion, immune evasion or the development of a septic shock.22 
To date, protease inhibitors have been approved for the treatment of HIV (e.g. ritonavir, 7, Figure 
3) or HCV (e.g. simeprevir).23 For bacterial infections however, no protease inhibitor is in clinical 
use yet.23,24 
Still, this class of enzymes offers promising drug targets to develop novel antibacterial agents, 
which has become a matter of utmost importance in a time when mankind is facing the threat 
imposed by antibiotic resistant bacteria.23–27 
 
 
Figure 3. Structures of protease inhibitors in clinical use: captopril (4),5 vorinostat (5),21 argatroban (6),5 
ritonavir (7)23 
 
1.2 Antibiotic Resistance 
 
The introduction of antibiotics for the treatment of bacterial infections is one of the most 
tremendous achievements of modern medicine.28 Starting with the discovery of penicillin and the 
sulfonamides in the late 1920s and 1930s, a “golden era” evolved, when most of the currently used 
antibiotics were developed.28,29 These developments led to the assumption that “It is time to close 
the book on infectious diseases”, a much-quoted misconception attributed to Dr. William H. 
Stewart, US Surgeon General in the late 1960s.30 Despite the lack of evidence that Dr. Stewart ever 
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made this statement,31 this urban legend excellently sums up the underestimation of a serious 
medical problem: antibiotic treatment is becoming ineffective due to the development of 
resistance.32 Remarkably, resistance toward sulfonamides was already reported in the late 1930s28,33 
and penicillinases were first described in 1940.34  
In his Nobel lecture in 1945, Sir Alexander Fleming even mentioned the possibility of resistance 
development by underdosage of antibiotics.35 Further reasons for the increasing ineffectiveness of 
antibiotics include their excessive use in animal husbandry, their misuse for the treatment of non-
bacterial infections or poor patient compliance.36,37 This has led to the selection of bacteria 
insensitive to multiple drugs like the so-called “ESKAPE” bugs.38 More recently, the WHO has 
addressed highly critical pathogens creating a list of priority pathogens, with a special focus on 
Gram-negative bacteria like Pseudomonas aeruginosa or Acinetobacter baumanii.39 Since 
permeation of the Gram-negative cell wall proves extremely challenging, these bacteria are 
particularly problematic to treat.40 Clearly, efforts to decelerate resistance formation must include 
a reduction of antibiotic use in livestock and stewardship strategies.37,39 On top of that, there is a 
dramatic need for the development of novel drugs against bacterial infections.37,39,41,42 
Paradoxically, the increasing emergence of resistant bacteria is accompanied by decreased 
industrial efforts to develop novel antibiotics.41–43 This is partly due to the reduced profit prospects 
of novel antibacterial drugs, given the relatively short time of administration compared to the 
treatment of chronic diseases, and the fact that novel antibiotics are likely to be used as reserve 
drugs.42,43 
Most of the newly approved antibacterial agents of the last decades were derivatives of existing 
classes, with only two new classes being applied for systemic treatment.44 The currently used 
antibiotics target essential processes in the bacterial life cycle, such as cell wall synthesis, DNA 
replication or protein biosynthesis.29 This leads to a high selection pressure on the bacteria and 
consequently favors the formation of resistance.45 In order to avert a “post-antibiotic era”32 where 
routine infections cannot be treated anymore, the development of novel treatment options is a matter 
of utmost urgency.39,41 Notably, teixobactin46 and griselimycin47 represent two examples of recently 
reported anti-bacterial compounds with the promise of low resistance formation. 
To the end of increasing the effectiveness of novel antibiotics as well as reducing resistance 
formation by a different mechanism of action, there has been a recent paradigm shift toward the 
development of anti-infectives targeting bacterial virulence.33  
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1.3 Developing Novel ‘Pathoblockers’ to Tackle Bacterial Virulence 
 
The term ‘virulence’ is a relative measure for the capacity of a pathogen to harm its host.48 Upon 
infection with bacteria, disease progression and evasion of the host immune response is promoted 
by virulence factors such as toxins, proteases, adhesins, secretion systems or siderophores.49 In 
order to develop new anti-infective drugs combating bacterial pathogenicity, these virulence factors 
are considered to be attractive targets.33,50–52  
The pathoblocker approach largely extends the number of potential drug targets, since these are no 
longer limited to factors essential for the bacterial life-cycle.33,50,52 In addition to directly interfering 
with virulence factors, it is also possible to inhibit their formation by blocking e.g. bacterial quorum 
sensing networks53 or oxidative protein folding.50 Since bacteria are ‘disarmed’ rather than impaired 
in their viability and growth (Figure 4), there is lower selection pressure which should reduce the 
formation of resistance.33,50–52 Besides, the absence of growth-inhibiting properties would make 
these drugs less attractive for the use in animal husbandry, which eliminates another important 
factor contributing to the formation of resistance.52 Targeting pathogen-specific pathways, anti-
virulence agents also hold the promise of reduced side-effects since human signaling pathways are 
not affected.51 Pathogen-specificity further limits the transmission of resistance genes to other 
bacteria via horizontal gene transfer.52 Additionally, these agents would not harm the human 
microbiome, contrary to conventional antibiotics which can lead to severe complications by 
damaging the commensal flora.54 Once their pathogenicity is reduced, the bacteria could then be 
cleared from the host either by the immune system or by conventional antibiotics.33,51 
 
Figure 4. Schematic comparison of the action of conventional antibiotics to the inhibition of bacterial 
virulence. Adapted from Heras et al.50 The structure of the PQS molecule was taken from Wagner et al.55 
and the image of P. aeruginosa was created by M. Empting. 
 
The hypothesis that these drugs are less likely to cause resistance has been critically questioned by 
Allen et al.56 In fact, resistance toward anti-virulence drugs has been observed, even in clinical 
isolates.57,58 Allen et al. suggest that resistance development toward anti-virulence agents depends 
on whether the respective virulence factor is beneficial for the bacteria or not.56 They argue that 
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addressing beneficial virulence factors could select for resistance, as for example a mutation in the 
target of virstatin led to better colonization of mice by Vibrio cholerae.57 However, if this protein 
is only expressed at the site of infection, resistance formation will be reduced due to the minor 
selection pressure on the commensal population.56 Consequently, the development of ‘evolution-
proof’ drugs is possible, but depends on the selection of the target and the environment of 
antibacterial treatment.56 
To date, several anti-virulence drugs are in development, with the only FDA-approved drugs being 
immunoglobulins that target extracellular virulence factors.52 Several small-molecule inhibitors are 
in preclinical development, like for example antagonists for P. aeruginosa RhlR59 or LasR,60 but 
none of them has been approved for clinical use yet.52 
1.4 Targeting LasB from Pseudomonas aeruginosa 
1.4.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative, aerobic nosocomial human pathogen.61 It is a leading 
cause for infections of cystic fibrosis patients, often with fatal outcome.62,63 According to the Cystic 
Fibrosis Foundation, in 2016 nearly every second CF patient was infected with P. aeruginosa, with 
17.7% of the strains showing multi-drug resistance.64 This pathogen is further responsible for 
urinary tract infections, keratitis and wound infections, especially in individuals suffering from burn 
wounds.65 As resistant strains are emerging while new treatment options are missing, the WHO has 
recently classified P. aeruginosa as one of the three most critical pathogens on its priority list for 
global research and development.39  
Several resistance mechanisms have been reported, including target mutations, inactivation of 
β-lactams by β-lactamases or compound efflux.66,67 Another major cause for antibiotic resistance of 
P. aeruginosa is the formation of biofilms.66 The bacterial biofilm is a matrix of extracellular 
polymeric substances such as polysaccharides, proteins, lipids or extracellular DNA (eDNA), which 
embeds the bacteria.68 Surrounded by the biofilm matrix, these are significantly less sensitive to 
antibiotic treatment and to host defense mechanisms like phagocytosis.69 Extracellular DNA, which 
is a major component of the P. aeruginosa biofilm,70 leads to reduced permeability of the outer 
membrane and to acidification of the biofilm, causing resistance toward human antimicrobial 
peptides (AMPs)71 and to aminoglycosides.72 Biofilm formation further favors adherence to medical 
devices such as urethral or central venous catheters, thereby contributing to the establishment of 
hospital-acquired infections.73,74  
In order to combat the threat posed by resistant P. aeruginosa, there is a special focus on virulence 
factors as potential drug targets.55,75 P. aeruginosa produces numerous virulence factors 
contributing to disease progression.76 On the one hand these can be cell-associated, like for example 
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pili, lipopolysaccharides or lectins which play important roles for adhesion and colonization.76,77 
Accordingly, lectin inhibitors have been shown to inhibit host cell invasion78 and biofilm 
formation.79 On the other hand, there are secreted toxins including proteases, hemolysins, HCN or 
the pigment pyocyanin.76,80 Playing pivotal roles in the establishment of an acute infection by tissue 
invasion and dissemination,77 extracellular factors represent attractive targets.55 Virulence factor 
expression in P. aeruginosa is controlled by a network of population-dependent signaling cascades, 
known as quorum sensing.81 Key players of this network have been addressed in drug discovery 
campaigns, including the multiple virulence factor regulator PqsR,82,83 or PqsD, an enzyme crucial 
for signal molecule biosynthesis.84 Compounds targeting these enzymes need to be cell-wall 
permeable, due to the intracellular location of the QS circuit.81 A substantial advantage of 
addressing secreted targets is the fact that there is no need to cross the Gram-negative cell wall, 
which is very challenging due to the presence of two membranes.67,85 
A key element of this work is the extracellular virulence factor elastase (LasB), which plays a 
pivotal role in host colonization and evasion of the host immune response and thereby significantly 
contributes to disease progression upon infection with P. aeruginosa.86 
 
1.4.2 Properties and Functions of LasB 
LasB is a zinc-metalloprotease secreted by P. aeruginosa.87 It is encoded by the lasB gene as a 53.4 
kDa preproenzyme, whose signal sequence (2.4 kDa) is cleaved upon membrane passage into the 
periplasm, where the 18 kDa propeptide is removed to yield mature LasB (33 kDa).88,89 The 
propeptide stays non-covalently attached to the mature protease during secretion into the 
extracellular space, where it is degraded.88,90 The N-terminal domain of the protease is formed 
mainly by antiparallel β-strands, while the C-terminal domain is predominantly α-helical with the 
active site being located in between these domains (Figure 5).91 The resulting tertiary structure of 
LasB is highly similar to thermolysin from Bacillus thermoproteolyticus, why it belongs to the 
thermolysin (M4) family of ‘Glu-zincin’ enzymes.91,92 Accordingly, conserved amino acid residues 
are the zinc-coordinating His-140, His-144 and Glu-164, as well as Glu-141, Tyr-155 and His-223 
which are essential for catalysis.91 LasB is active against a variety of substrates, including the 
connective tissue components collagen and elastin or laminin.87,93,94 Generally, bulky hydrophobic 
amino acids at the N-terminal cleavage site of the protease are preferred.95 
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Figure 5. Apo structure of LasB (PDB Code 1EZM) visualized in standard orientation.96 The N-terminal 
domain consisting mainly of β-strands is shown at the top, the α-helical C-terminal domain at the bottom. 
Conserved residues are highlighted in a zoom in view. Zinc is depicted as a gray sphere, calcium as green 
one. 
 
Apart from LasB (also known as pseudolysin), P. aeruginosa produces and secretes several other 
proteases.97 Aeruginolysin (alkaline protease) can also contribute to tissue degradation in the 
infection process, but its proteolytic potency is low compared to LasB.97,98 LasA (staphylolysin) is 
a zinc-metalloprotease capable of lysing staphylococci.99,100 It has low elastolytic activity but makes 
elastin more susceptible to cleavage by LasB by breaking Gly-Gly bonds.99 LasA itself is processed 
extracellularly by the action of LasB.88 Furthermore, P. aeruginosa expresses lysyl endopeptidase 
(protease IV), a serine protease involved in immune evasion.101 Out of these proteases, LasB is the 
most abundant one and possesses the highest endopeptidase activity.97 
LasB is of crucial importance for the colonization and invasion of the host upon infection with 
P. aeruginosa.86,102 This is due to its tissue-damaging properties which can lead to dermonecrosis,103 
airway104 and cornea damage105 or disruption of cell junctions.106,107 It further plays a substantial 
role in the evasion of human response mechanisms by cleaving numerous components such as 
cytokines,108 complement factors,109 the immunoglobulin IgG110 or surfactant proteins.111 Using an 
in vivo model, Kuang et al. demonstrated LasB to reduce phagocytosis of P. aeruginosa by 
degrading surfactant protein-A in mice lungs.112 LasB is further known to downregulate IL-6113 and 
to disarm pulmonary defense receptor PAR2.114 Additionally, it impairs wound healing by 
inhibiting the growth of fibroblasts.115 Saint-Criq et al. have recently reported LasB to target a 
receptor mutated in CF patients, making lung epithelia more susceptible for infections.113 LasB also 
degrades flagellin, thereby preventing it from inducing an immune response.116 It further evades the 
host response by cleaving a peptide from thrombin which eventually inhibits pro-inflammatory 
processes.117 The human AMP LL-37 has been found to be cleaved and thereby inactivated by LasB 
as well.118  
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On top of that, swarming motility as well as biofilm formation of P. aeruginosa were shown to 
depend on LasB.119 Regarding the involvement of LasB in biofilm formation, two possible 
mechanisms have been reported: Kamath et al. have found LasB to proteolytically activate 
nucleoside diphosphate kinase (NDK), an enzyme generating GTP for the formation of alginate, 
which is an important constituent of the biofilm.120,121 This has been related to retention of LasB in 
the periplasm, where NDK activation takes place.121 Yu et al. have linked biofilm formation to the 
regulation of rhamnolipids, which is associated to the lasB gene.122 
Taken together, these versatile, harmful functions in the infection process of P. aeruginosa make 
LasB an attractive anti-infective drug target.104,113,123 
 
1.4.3 LasB Inhibitors 
Since LasB is a zinc-metalloprotease, it is inhibited by zinc chelators like EDTA or 
phenanthroline.87 Inhibitor development has further been based on zinc-chelating moieties like 
thiols or hydroxamates, which is a common strategy in protease drug discovery.14 This approach 
has led to thiol-containing peptides with protective effects on keratitis in rabbits.105,124 Kessler et al. 
have also demonstrated thiol and hydroxamate-based compounds to inhibit elastin and cartilage 
cleavage.125 In line with the high structural similarity, several peptide hydroxamates are potent 
inhibitors of LasB and thermolysin alike.126 Cathcart et al. have presented preference of nonpolar 
aliphatic and aromatic amino acids at the P1’ position of metal-chelating dipeptides for inhibition 
of LasB, which is in agreement with the substrate specificity of LasB.127 They have demonstrated 
thiol 8 (Figure 6) to significantly reduce P. aeruginosa biofilm formation and to completely 
eradicate biofilms in combination with antibiotics.128 The first nonpeptidic LasB inhibitors have 
been introduced by Garner et al.129 These heterocyclic zinc chelators, as well as a tropolone 
derivative (9)130 impair swarming of P. aeruginosa. Besides, heterocyclic inhibitors developed as 
analogs of the Pseudomonas quinolone signal (PQS) are also active on LasB with low micromolar 
IC50s.131 Alternative nonpeptidic inhibitors are the mercaptoacetamides described by Zhu et al. to 
increase the survival time of Caenorhabditis elegans in an early in vivo assay (10).132 In addition to 
these small molecules, monoclonal antibodies also serve as LasB inhibitors.133  
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Figure 6. Structures of selected LasB inhibitors: peptidic mercaptoacetamide 8,128 tropolone 9,130 N-aryl 
mercaptoacetamide 10132 and phosphoramidon (11).134 
 
 
The mentioned nonpeptidic compounds have low micromolar in vitro activities on LasB,129,130,132 
while some peptide-based compounds are active in the submicromolar range.105,128 This holds true 
for the thermolysin-inhibitor phosphoramidon (11) as well.134,135 Regarding selectivity, the 
mercaptoacetamides were shown to be selective toward individual human proteases (MMP-2 and 
HDAC),132 while the thiol-based peptides did not impair the activity of MMP-2,-8, and -9.128 The 
non-peptidic inhibitors introduced by Fullagar, Garner et al. are not selective against MMP-2 and -9, 
except for the tropolone scaffold.130 A series of hydroxamate-based peptides presented by Adekoya 
et al. have been derived from MMP inhibitors, consequently lacking selectivity.136,137  
1.5 Targeting Clostridial Collagenases 
1.5.1 Clostridia 
Clostridia are Gram-positive, obligate anaerobic bacteria which are ubiquitously present in soil or 
wastewater and form also part of the human commensal flora.138,139 Several clostridial species can 
cause severe diseases like tetanus (C. tetani), botulism (C. botulinum), foodborne illness 
(C. perfringens) or gas gangrene (C. perfringens, C. histolyticum).139 The incidence of gas gangrene 
is perilously increased in cases of natural disasters or during times of war.140 Due to its rapid 
progress, which can also result in shock or organ failure, amputation is often necessary despite 
antibiotic treatment.141 The strain C. difficile is a cause for severe nosocomial diarrhea as well as 
pseudomembranous colitis, which can be a consequence of antibiotic treatment.54,139,142 Resistance 
toward multiple antibiotics, mainly caused by target mutations,143 seriously hamper the treatment 
of C. difficile infections and make the development of novel treatment options an urgent 
necessity.54,142 Antibiotic resistance has been observed in other Clostridium species as well.144 
Clostridial pathogenicity is based on the production and secretion of numerous toxins.145 A few of 
these toxins are classified as biological warfare agents, including botulinum neurotoxin from 
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C. botulinum, which is the most toxic substance known.146 Collagenases which are expressed and 
secreted by pathogenic clostridia have hydrolytic activity on components of the connective tissues 
and represent crucial virulence factors.139,145,147 In addition to invasion of the host, they are also 
important for the acquisition of nutrients and toxin diffusion.145 Based on a mouse myonecrosis 
model, Awad et al. concluded that collagenase is not crucial for the establishment of an infection 
by C. perfringens, but rather the production of α-toxin.148 In contrast, the invasiveness of 
L. interrogans was clearly related to the in vivo expression of extracellular collagenase, highlighting 
the significance of these harmful proteases for bacterial pathogenicity.149 
 
1.5.2 Properties and Function of C. histolyticum Collagenases 
For the degradation of connective tissue, one of the most efficient systems that is known are the 
collagenases secreted by C. histolyticum.150 This bacterium produces two classes of these proteases, 
which are encoded by the colH or colG gene, respectively.151 Contrary to mammalian MMPs, which 
cleave collagen at a single cleavage site, clostridial collagenases are capable of attacking it at 
multiple sites and cleaving it to small peptides.152 This specificity is due to a high selectivity of the 
active site of these enzymes for the GPX sequence,153 which is a characteristic motif of the collagen 
triple helix.154  
ColH and ColG are classified into the M9 family of metallopeptidases.155 Similar to LasB and 
thermolysin, they are ‘Glu-zincins’, harboring the characteristic zinc-binding motif ‘HEXXH’ with 
a downstream glutamate as third zinc ligand.156 These two metalloproteases of ~115 kDa are 
composed of a saddle-shaped, N-terminal collagenase unit and a collagen recruitment unit, which 
is composed of one to two collagen binding and polycystic kidney disease-like domains (Figure 
7).151,157–160 The catalytic subdomain of ColG adopts a thermolysin-like fold, including a five-
stranded β-sheet with the edge strand involved in substrate recognition.159 The collagenase unit 
comprises an activator domain and a peptidase domain which is, unlike the full collagenase unit, 
not capable of degrading collagen.159 In proximity to the catalytic zinc, a calcium binding site was 
discovered which is necessary for full collagenase activity.158 Another important structural feature 
of these proteases is a double Gly-motif 28 amino acids downstream of the active site, forming a 
secondary S1´ oxyanion pocket.159,160 The peptidase domain of ColG displays structural similarity 
to the ColH peptidase domain, but interestingly an even higher similarity to the one of ColT from 
C. tetani.158 Furthermore, ColG and ColA from C. perfringens share the same domain architecture 
and have high sequential similarity.151  
Interestingly, ColH from C. histolyticum is used as a therapeutic for Dupuytren’s Disease161 which 
is characterized by a pathologic overproduction of collagen in hands,162 and is also approved for the 
reduction of penile plaque in Peyronie’s disease.163 Further applications are wound debridement164 
or human cell islet isolation.165 
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Given their detrimental role in the establishment of infections, clostridial collagenases represent 
prime targets for the development of novel anti-infective agents.27,160 
 
 
Figure 7. Domain organization of ColH and ColG. PKD: polycystic kidney disease like-domain, CBD: 
collagen binding domain. Adapted from Eckhard et al.158 
 
1.5.3 C. histolyticum Collagenase Inhibitors 
Similar to LasB inhibitors (chapter 1.4.3), several collagenase inhibitors are based on small peptides 
containing different zinc-binding groups such as thiols,166 phosphonamides167,168 or phosphonic 
amides like isoamyl-PO2-GPA (12, Figure 8),167 with low micromolar to nanomolar activities. 
Aldehyde and ketone substrate analogs are less active with three-digit micromolar IC50s.169 As 
expected, zinc chelation by phenanthroline leads to collagenase inhibition, too.170 The thermolysin 
and LasB inhibitor phosphoramidon is also active on ColH, with an IC50 of 16 µM.171 Modification 
of natural coumarin derivatives isolated from Viola yedoensis have led to nanomolar collagenase 
inhibitors like compound 13.171 Supuran and Scozzafava have introduced hydroxamate derivatives 
of valin,172 glycine173 or alanine174 with nanomolar activities (for a selected example see 14). Similar 
inhibitors contain dibenzo-suber(en)yl moieties,175 thiadiazole rings,176 or succinate/iminodiacetic 
acid.177 
Being partly derived from known MMP inhibitors, these compounds lack selectivity and are rather 
potent inhibitors of several MMPs alike.172–177  
 
 
Figure 8. Structures of selected ColH inhibitors: isoayml-PO2-GPA (12),167 coumarin derivative 13,171 and 
succinyl hydroxamate 14.173 
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1.6 Matrix Metalloproteases (MMPs) 
 
MMPs are zinc-metalloproteases belonging to the M10 family of peptidases.4 An important 
function of MMPs is the degradation and turnover of extracellular matrix (ECM) components, but 
they are also heavily involved in the regulation of inflammatory processes, apoptosis, cell 
differentiation and growth.178,179 More recently, there has been insight into further intracellular 
functions of MMPs, like transcription factor activity.180 The expression of MMPs is induced by e.g. 
components of the immune system or hormones and their activity is further regulated by tissue 
inhibitors of metalloproteinases (TIMPs) or α2-macroglobulin.179,181 Dysregulation of MMP 
function can be the reason for various diseases like arthritis, cardiovascular diseases, inflammation 
and cancer.178,179,182 Therefore, these proteases were considered promising targets for cancer 
therapy.2,19,183  
Generally, MMPs are formed by a propeptide, a catalytic domain containing the active site zinc, 
the linking ‘hinge region’ and a hemopexin domain important for substrate recognition.178,179 
Presence and multiplicity of these domains vary, depending on the function of the respective 
enzyme.178,179 In humans, more than 20 different MMPs are present, which are classified based on 
their function as collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), as well as stromelysins, 
matrilysins and membrane-type MMPs.178 With regard to the depth of their S1´ binding pocket, 
MMPs are further divided into deep (e.g. MMP-3, -12, -14), intermediate (e.g. MMP-2, -8, -9) and 
shallow pocket MMPs (e.g. MMP-1, -7).184 The structural differences in the S1´ site are believed to 
grant access to inhibitors specifically targeting individual MMPs.16 Similar to the bacterial 
collagenases described above, MMPs share the ‘HEXXH’ motif, yet the third zinc ligand is a 
histidine instead of a glutamate.178  
In the last decades, MMP inhibitors like batimastat largely failed in clinical trials, partly because of 
poor oral bioavailability but mainly because of unwanted side effects, which were due to the 
unselective inhibition of various MMPs or other metalloproteases.2,15–19 Given that many MMP 
inhibitors contain zinc chelating moieties, poor selectivity can to some extent be attributed to the 
disproportionate contribution of the zinc chelating moiety to compound binding.16 Therefore, there 
is also considerable interest in targeting less conserved binding sites, like the hemopexin domain.19 
It has now become clear that the physiological function of MMPs can be extremely versatile, 
making them in part targets and anti-targets at the same time.185 Along with partially poor trial 
design,15,17 the heterogeneity of MMP function is another reason for the failure of MMP inhibitors 
in clinical studies.186 As a consequence, selectivity toward other proteolytic enzymes is of high 
importance in protease drug discovery, with a special emphasis on MMPs as far as zinc 
metalloprotease inhibitors are considered.5,15,185  
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2 Aim of the Thesis 
 
Because of their essential role in numerous processes regulating human health and disease, 
proteases are regarded as attractive drug targets and many protease inhibitors have been approved 
for clinical use. However, several drug discovery campaigns toward novel protease inhibitors failed 
i.a. for the reason of poor selectivity of the drug candidates toward other proteolytic antitargets. 
Developing selective inhibitors proves challenging, especially in case of active site-directed 
compounds. Yet, this approach is particularly attractive for the development of novel antibacterial 
drugs. In a time when humankind is facing the increasing emergence of bacteria which are resistant 
to commonly used antibiotics, this is a matter of utmost importance. In the search of new antibiotics 
with novel modes of action, the concept of targeting bacterial virulence has gained significant 
attraction. Since these ‘pathoblockers’ are supposed to reduce selection pressure on bacteria, they 
are considered as a promising new weapon to combat the threat imposed by these resistant 
pathogens. In this context, extracellular proteases represent conceptually attractive drug targets. 
They contribute essentially to host colonization and immune evasion and prove particularly 
advantageous due to their extracellular localization, which allows circumvention of potential 
permeability issues. 
The objective of this thesis was the development of inhibitors targeting two bacterial collagenases: 
ColH from the Gram-positive C. histolyticum and LasB from the Gram-negative P. aeruginosa. 
These pathogens cause severe diseases like gas gangrene (C. histolyticum) and fatal lung infections 
in immunocompromised or CF patients (P. aeruginosa). Considering the lack of selectivity of many 
known inhibitors of ColH and LasB, there was a special focus on selectivity toward mammalian 
MMPs. 
In previous work at HIPS-DDOP, an SPR screening of a focused protease inhibitor library was 
performed, which was followed by a functional assay of the binding hits in collaboration with the 
University of Salzburg. The aim of this work was the establishment of an SAR of the most 
promising class of hits, along with their biophysical and biological characterization. These efforts 
also included resynthesis of the most promising hits. The results regarding ColH are outlined in 
chapter 3.1. 
The second part of this work aimed at the discovery of LasB inhibitors (chapter 3.2). To this end, a 
reported FRET-based assay was used to perform a functional screening of the aforementioned 
library and a fragment library. In order to overcome the problem of quenching compounds causing 
false-positive results, an LC-MS based counterscreen was developed. Further work aimed at SAR 
establishment, X-ray structure-based optimization and the biological evaluation of lead inhibitors 
including selectivity toward human MMPs and in vivo efficacy in G. mellonella. 
15 
 
 
 
The third part of this thesis describes synthetic efforts to replace the thiol function of the lead LasB 
inhibitor (chapter 3.3). This chemical work was again accompanied by further biological analysis 
of LasB inhibition. Here, the objective was to analyze effects on key resistance mechanisms of 
P. aeruginosa, such as biofilm formation, eDNA release and the cleavage of the human AMP 
LL-37. 
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3 Results 
3.1 Chapter A: Discovery of a Potent Inhibitor Class with High Selectivity toward 
Clostridial Collagenases187 
Schönauer, E.┴; Kany, A. M. ┴; Haupenthal, J.; Hüsecken, K.; Hoppe, I. J.; Voos, K.; 
Yahiaoui, S.; Elsässer, B.; Ducho, C.; Brandstetter, H.; Hartmann, R. W. 
┴ these authors contributed equally 
Reprinted with permission from J. Am. Chem. Soc. 2017, 139, 12696–12703. 
DOI:10.1021/jacs.7b06935 
Copyright (2017) American Chemical Society 
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3.2 Chapter B: Binding Mode Characterization and Early in Vivo Evaluation of 
Fragment-Like Thiols as Inhibitors of the Virulence Factor LasB from 
Pseudomonas aeruginosa188 
Kany, A. M. ┴; Sikandar, A. ┴; Haupenthal, J.; Yahiaoui, S.; Maurer, C. K.; Proschak, E.; 
Köhnke, J.; Hartmann, R. W. 
┴ these authors contributed equally 
Reprinted with permission from ACS Infect. Dis. 2018, DOI:10.1021/acsinfecdis.8b00010. 
[Epub ahead of print] 
Copyright (2018) American Chemical Society 
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3.3 Chapter C: Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic 
Acid-Based LasB Inhibitor 
 
The following persons contributed experimentally to this chapter: 
Andreas M. Kany: performed syntheses and the in vitro inhibition assay, established and 
performed the LL-37 assay, planned Biofilm/eDNA assays 
Asfandyar Sikandar: purified LasB and modified the protocol, performed LasB 
crystallization experiments and structure determination 
Dr. Martin Empting: performed structural superimposition of LasB with MMP structures and 
image preparation 
This part of the thesis has been submitted to ACS Chem. Biol. 
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Supporting Information to Chapter C 
 
 
Table S1. Data collection and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistics for the highest-resolution shell are shown in parentheses. 
  
 
LasB-7 
Resolution range 61.26  - 2.1 (2.175  - 2.1) 
Space group P 21 21 21 
Unit cell 43.7 53.0 122.5 90 90 90 
Total reflections 88777 
Unique reflections 16581 (1575) 
Multiplicity 5.3 (5.4) 
Completeness (%) 95.88 (93.64) 
Mean I/sigma(I) 4.3 (1.9) 
R-merge 0.257 (0.689) 
R-work 0.1828 (0.2210) 
R-free 0.2102 (0.3084) 
Number of non-hydrogen atoms 2641 
  macromolecules 2317 
  ligands 29 
  solvent 295 
Protein residues 300 
RMS(bonds) 0.004 
RMS(angles) 0.94 
Ramachandran favored (%) 95.27 
Ramachandran allowed (%) 4.39 
Ramachandran outliers (%) 0.34 
Rotamer outliers (%) 0.00 
Clashscore 2.00 
Average B-factor 17.59 
  macromolecules 16.44 
  ligands 24.71 
  solvent 25.92 
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Figure S1. (A) Binding of the hydroxamate compound 7 leads to a closed conformation of the LasB active 
site. (B) In contrast, binding of the recently reported thiol inhibitor of LasB (1) arrests the enzyme in an open 
conformation. LasB is shown as a cyan surface representation, the active site zinc ion as a grey sphere and 
ligand molecules as grey/black sticks. 
 
 
Figure S2. Structures of published hydroxamate-based MMP-7 inhibitor 91 and MMP-3 inhibitor 10.2  
 
Figure S3. Structure of MMP inhibitor Batimastat.3  
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Synthesis 
4-((3,4-dichlorophenyl)amino)-4-oxobutanoic acid (3). 3,4-dichloroaniline (160 mg, 0.99 mmol) 
was placed in a crimp vial and dissolved in 5 mL of dioxane at 70°C. Succinic anhydride (105 mg, 
1.05 mmol) was added. The reaction was stirred at 70°C for 6 hours. Hydrochloric acid (2 M, 2 
mL) was added and the aqueous phase was extracted with ethyl acetate, washed with brine and 
dried over magnesium sulfate and concentrated under reduced pressure. The crude was purified 
using automated flash chromatography (reversed-phase: acetonitrile + 0.1% formic acid:water + 
0.1% formic acid 15:85 to 65:35) to yield the title compound as a white powder (152 mg, 59%). 1H 
NMR (300 MHz, DMSO-d6) δ ppm 2.37 - 2.49 (m, 4 H), 7.36 - 7.44 (dd, J = 8.8, 2.3 Hz, 1 H), 7.48 
(d, J = 8.8 Hz, 1 H), 7.93 (d, J = 2.2 Hz, 1 H), 10.21 (s, 1 H), 11.57 - 12.75 (br. s, 2 H); 13C NMR 
(75 MHz, DMSO-d6) δ ppm 28.6, 31.1, 118.9, 120.1, 124.3, 130.6, 131.0, 139.3, 170.7, 173.7; 
MS (ESI+) m/z 262 (M+H)+ 
(Z)-4-((3,4-dichlorophenyl)amino)-4-oxobut-2-enoic acid (4). 3,4-dichloroaniline (170 mg, 1.05 
mmol) was placed in a crimp vial and dissolved in 5 mL of dioxane at 70°C. Maleic anhydride (103 
mg, 1.05 mmol) was added. The reaction was stirred at 70°C for 6 hours. Filtration of the formed 
precipitate gave the title compound as a white powder (151 mg, 55%). 1H NMR (300 MHz, DMSO-
d6) δ ppm  6.32 (d, J = 11.9 Hz, 1 H), 6.48 (d, J = 11.9 Hz, 1 H), 7.50 (dd, J = 8.9, 2.4 Hz, 1 H), 
7.59 (d, J = 8.8 Hz, 1 H), 8.01 (d, J = 2.3 Hz, 1 H), 10.6 (s, 1 H), 12.76 – 13.04 (br s., 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 119.4, 120.5, 125.1, 130.1, 130.7, 131.0, 131.6, 138.8, 163.7, 
166.8; MS (ESI+) m/z 260 (M+H)+ 
Methyl-3-((3,4-dichlorophenyl)amino)-3-oxopropanoate (5). 3,4-dichloroaniline (500 mg, 3.1 
mmol) was dissolved in 10 mL of dichloromethane under cooling on ice. Triethylamine (850 µL, 
6.2 mmol) were added, followed stepwise by methyl malonyl chloride (520 µL, 4.9 mmol). The 
mixture was warmed to room temperature and stirred for 4 hours. The organic phase was washed 
with saturated ammonium bicarbonate solution. The crude was purified automated flash 
chromatography (petroleum ether:ethyl acetate 80:20 to 5:95) to yield the title compound as a white 
powder (548 mg, 67%). 1H NMR (300 MHz, DMSO-d6) δ ppm 3.49 (s, 2 H), 3.66 (s, 3 H), 7.45 
(dd, J = 8.9, 2.4 Hz, 1 H), 7.58 (d, J = 8.8 Hz, 1 H), 7.96 (d, J = 2.4 Hz, 1 H), 10.49 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 43.5, 52.0, 119.1, 120.3, 125.0, 130.8, 131.0, 138.8, 164.5, 167.8; 
MS (ESI+) m/z 262 (M+H)+ 
3-((3,4-dichlorophenyl)amino)-3-oxopropanoic acid (6). 5 (150 mg, 0.57 mmol) was dissolved in 
4 mL of tetrahydrofurane. Sodium hydroxide solution (2 M, 570 µL) was added, followed stepwise 
by 1.43 mL of water. The mixture was stirred at room temperature for 24 hours. The aqueous phase 
was extracted with diethyl ether. After addition of 5 mL of water, the aqueous phase was extracted 
with ethyl acetate, dried over magnesium sulfate and concentrated under reduced pressure to yield 
the title compound as a white powder (115 mg, 81%). 1H NMR (300 MHz, DMSO-d6) δ ppm 3.36 
(s, 2 H), 7.46 (dd, J = 8.9, 2.4 Hz, 1 H), 7.58 (d, J = 8.8 Hz, 1 H), 7.98 (d, J = 2.3 Hz, 1 H), 10.43 
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(s, 1 H), 12.48 - 12.94 (br. s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 44.0, 119.1, 120.2, 124.8, 
130.8, 131.0, 139.0, 165.1, 168.9; MS (ESI+) m/z 248 (M+H)+ 
N1-(3,4-dichlorophenyl)-N3-hydroxymalonamide (7). Hydroxylamine hydrochloride (106 mg, 1.52 
mmol) was dissolved in 10 mL of methanol. N,N-Diisopropylethylamine (280  µl, 1.68 mmol) was 
added. The mixture was stirred at room temperature for 30 minutes. 5 (100 mg, 0.84 mmol) was 
added and the reaction refluxed for 8 hours, followed by 16 hours at room temperature. The mixture 
was acidified with hydrochloric acid until pH 1 and extracted with ethyl acetate. The organic phase 
was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
The crude was purified using automated flash chromatography (reversed-phase: acetonitrile + 0.1% 
formic acid:water + 0.1% formic acid 20:80 to 100:0) to yield the title compound as a white powder 
(27 mg, 27%). 1H NMR (300 MHz, DMSO-d6) δ ppm 3.12 (s, 2 H), 7.48 (dd, J = 8.9, 2.4 Hz, 1 H), 
7.57 (d, J = 8.9 Hz, 1 H), 7.98 (d, J = 2.3 Hz, 1 H), 8.99 (s, 1 H), 10.42 (s, 1 H), 10.62 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 44.5, 119.6, 120.7, 125.3, 131.3, 131.5, 139.5, 165.6, 169.4; 
MS (ESI+) m/z 263 (M+H)+ 
N-(3,4-dichlorophenyl)-2-hydroxyacetamide (8). 3,4-dichloroaniline (200 mg, 1.23 mmol) and 
glycolic acid (94 mg, 1.24 mmol) were placed in a crimp vial. The vial was sealed and heated to 
130°C for 24 hours. The crude was purified using flash chromatography (petroleum ether:ethyl 
acetate 70:30 to 60:40) to yield the title compound as a white powder (156 mg, 58%). 1H NMR 
(300 MHz, DMSO-d6) δ ppm 4.00 (s, 2 H) 5.50 – 6.00 (br. s, 1 H) 7.56 (d, J = 8.9 Hz, 1 H) 7.70 
(dd, J = 8.8, 2.5 Hz, 1 H) 8.11 (d, J = 2.4 Hz, 1 H) 9.76 – 10.23 (br. s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 61.9, 119.7, 120.8, 124.8, 130.5, 130.8, 138.7, 171.5; MS (ESI+) m/z 220 (M+H)+ 
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4 Final Discussion 
 
The goal of this thesis was the discovery of inhibitors of bacterial collagenases, precisely ColH 
from C. histolyticum and LasB from P. aeruginosa. As described in the introduction, these 
extracellular enzymes prove attractive targets for the development of new anti-infectives targeting 
bacterial virulence, since they play a key role in the infection process of these pathogenic bacteria.  
Since LasB and ColH are zinc-metalloproteases, the drug discovery strategy was based on a focused 
protease inhibitor library (ActiTarg-P, obtained from TimTec). For the discovery of LasB 
inhibitors, a functional screening was performed, using a FRET-based assay supplemented by an 
LC-MS-based readout to exclude false-positives. The development of ColH inhibitors was based 
on the results of an SPR binding assay complemented with a secondary functional FRET assay. 
Interestingly, both screening campaigns yielded N-aryl mercaptoacetamides as most promising 
inhibitors. Although not derived from a fragment library, these compounds do represent fragments, 
fulfilling the criteria presented for fragment-based lead discovery in the so-called ‘rule of three’ 
(molecular weight <300 Da, number of hydrogen bond donors/acceptors ≤ 3, ClogP ≤ 3).189 Their 
inverse Structure-Activity Relationships (SAR) toward the two targets, the unprecedented high 
selectivity toward human MMPs along with the prodrug character will be discussed and compared 
in the following chapters. This is followed by a discussion of synthetic modifications and the 
evaluation of LasB inhibition in more complex cellular systems and an in vivo model. 
 
For the sake of clarity, compounds mentioned in this part of the thesis are denominated with the 
capital letter A, B or C referring to the respective manuscript, followed by an Arabic number 
corresponding to the numbering in each manuscript. 
4.1 SAR and Binding Modes of N-Aryl Mercaptoacetamides 
 
A central element of this work was the SAR elucidation of N-aryl mercaptoacetamides toward ColH 
and LasB. Interestingly, the functional assay results for a series of derivatives with varying 
substitution of the aromatic core revealed different structural properties to be favorable for the 
activity toward ColH (chapter A) and LasB (chapter B).  
 
In case of ColH, substitution in para-position to the aniline moiety is highly beneficial for 
inhibition. There is, for example, a more than 300-fold difference in activity between p-methoxy 
derivative A5 (IC50 0.071 ± 0.009 µM) and its o-analogue A11 (IC50 26 ± 4 µM). Similarly, p-Cl 
substituted A7 (IC50 0.19 ± 0.02 µM) is considerably more active than o-Cl derivative A12 (IC50 31 
± 7 µM) or m-Cl derivative A9 (IC50 19 ± 3 µM). The most potent ColH inhibitor is 
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N-(4-acetylphenyl)-2-mercaptoacetamide with an IC50 of 0.017 ± 0.002 µM (A13, or 0.010 ± 0.002 
µM when its prodrug A3 is concerned, Table 1). Two additional compounds with IC50 values in the 
two-digit nanomolar range bear methylester (A4) or methoxy (A5) groups para to the aniline 
moiety, demonstrating a strong preference for polar, hydrogen-bond accepting functions. 
The observed SAR could be rationalized by the X-ray crystal structure of A13 in complex with the 
ColH peptidase domain. The hydrolysis product of thiocarbamate prodrug A3 was found to bind to 
the S1-S3 site of the protease, forming a hydrogen bond with the main-chain oxygen of Tyr428 in 
S1 and the main-chain nitrogen of Glu430 in S3 via the acetyl function and a bridging water 
molecule. This interaction explains the preference for hydrogen bond-accepting moieties in para-
position to the aniline. Considering the tremendous drop in activity upon removal of the para-acetyl 
moiety (A1, IC50 25 ± 6 µM), these hydrogen bonds seem to be of particular importance.  
 
Table 1. Structure and inhibition of ColH and LasB by the respective lead inhibitors. 
Cp. A3/B1 A25/B27 
Structure 
  
ColH IC50 [µM] 0.010 ± 0.002 86 ± 2% inhibition @100 µM 
LasB IC50 [µM] 73.1 ± 2.5 6.2 ± 0.3 
 
 
As mentioned above, the SAR toward LasB showed a different activity profile of the N-aryl 
mercaptoacetamides. Notably, the best ColH inhibitor A3 is one of the weakest LasB inhibitors 
described in chapter B (B1, IC50 73.1 ± 2.5 µM). Likewise, the activity of the very potent ColH 
inhibitors A4 and A5 on LasB is in the high two-digit micromolar range (B24, IC50 81.5 ± 2.5 µM 
and B23, IC50 47.7 ± 1.0 µM). Contrary to what was observed for ColH, nonpolar substituents, 
especially halogens, were advantageous for activity on LasB, which is exemplified by o-, m-, or 
p-Cl derivatives B9, B12 and B17, with IC50 values between 14 and 19 µM. This is one of several 
examples pointed out in the chapter, which highlights that the position of a substituent does not 
substantially affect the activity of the compound. Yet, addition of a second substituent to the 
aromatic core of B17 (IC50 15.7 ± 0.4 µM) generally improved the activity and led to the best LasB 
inhibitors B26-B28 with one-digit micromolar IC50 values (5.9 – 7.2 µM). These observations are 
in accordance with studies reporting LasB to prefer bulky, hydrophobic amino acids at the cleavage 
site of its substrates.95,127 
As expected, the co-crystal structure of B36 with LasB revealed the thiol function of the inhibitor 
to chelate the active site zinc. In contrast to the ColH-A13 complex, a primed binding mode was 
discovered, with the unexpected binding of a second molecule in an antiparallel orientation toward 
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the zinc-chelating one (a more detailed binding mode analysis is subject of chapter 4.3). Actually, 
the presence of two molecules in the X-ray structure is in disagreement with the observed Hill slope 
of 1 in the in vitro assay. Apparently, for full inhibition only one binding event is necessary. 
Consequently, the second molecule appears to have no impact on inhibition and its absence in 
solution cannot be excluded. 
 
Considering the notable difference in activity of the best hit toward the respective target, which is 
in the low nanomolar range for ColH but only in the low micromolar range for LasB, the question 
arises what causes this disparity. The SAR on ColH is sharp, given that several derivatives show 
only less than 50% inhibition at 100 µM (A32-A35). The co-crystal structure with the best inhibitor 
revealed that literally all functional groups of A13 undergo distinct interactions with active site 
amino acid residues. Accordingly, this small molecule represents a highly specific ‘key’ perfectly 
fitting into its ‘lock’, the protease binding site. This is remarkable for an inhibitor of that size, given 
that fragments are normally low-affinity ligands.190 Clearly, this is related to the presence of a thiol 
moiety as a ‘warhead’ binding the catalytic zinc, which results, as determined using ITC, in 
enthalpy-driven binding of this compound class. 
The SAR deduced for LasB is generally less sharp, with a much smaller difference in activity 
between the best (B26, IC50 5.9 ± 0.3 µM) and the weakest N-aryl mercaptoacetamide 
(B16, IC50 127.2 ± 3.5 µM). The X-ray co-crystal structure revealed several interactions between 
the inhibitor and the binding pocket, but not for the aromatic core or the amide nitrogen of the zinc-
chelating molecule as in ColH-A13. Contrary to that complex, edge strand interactions are not 
achieved by the zinc-chelating B36A, but rather by the second thiol bound. Hence, in order to 
improve the activity on LasB, a more specific ‘key’ engaged in more interactions with the binding 
site would be needed. A rational strategy toward this end is the N-benzylation/-alkylation approach 
outlined in chapter B. The fact that all the resulting compounds were active on the target (B63-B74) 
indicates a high tolerance for different substitution patterns, which could be due to the 
comparatively large binding site of LasB. Presumably, these new inhibitors do not possess an 
optimal conformation for binding to LasB in the mode that was suggested by molecular modelling. 
An alternative approach toward a more specific (and hence more potent) ‘key’ could be the 
development of a thiol inhibitor that is capable of leading to a closure of the active site by combining 
the interactions of the two molecules present. 
 
Regarding the distinct differences between the two targets, the herein discussed SAR and co-crystal 
structures clearly allow the rational, structure-based design of novel anti-infectives specifically 
targeting LasB or ColH. 
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4.2 Prodrug Character of the Thiocarbamate Function 
 
Prodrugs are compounds which have to undergo transformation after they are administered, in order 
to yield the actual active drug.191 This approach has proven useful for crossing biological barriers 
(like the blood-brain barrier), or when drug solubility needs to be altered, as for example in case of 
intravenous application of otherwise poorly water-soluble drugs.192,193 Furthermore, prodrugs are 
used to enhance the chemical stability of drugs.192 Mostly, they are converted enzymatically by e.g. 
esterases, phosphatases or hepatic CYP enzymes, but non-enzymatic hydrolysis can also take 
place.193 Prominent protease inhibitors equipped with a prodrug moiety are ACE inhibitors like 
ramipril.2 Examples for masked thiols are clopidogrel194 or racecadotril, where the active metabolite 
thiorphan is equipped with an acetate function.195 A similar approach has been used for N-aryl 
mercaptoacetamides.132  
The sulfhydryl groups of the inhibitors presented in this study are protected with a carbamate 
function, which liberates free thiols after hydrolysis (Figure 9). Carbamates have been used to 
design prodrugs of phenolic compounds, mostly to overcome metabolic instability.196 The 
somewhat fortuitous discovery of the prodrug character of our inhibitors prompted us to closely 
investigate their stability. Using an LC-MS-based assay it was shown that thiocarbamates hydrolyze 
rapidly in aqueous buffers, in absence of hydrolytic enzymes. On the contrary, carbamates are 
generally known to be stable.197 
 
 
Figure 9. General scheme for the formation of active thiols from thiocarbamate prodrugs. 
 
Comparison of the formation of N-(4-chlorophenyl)-2-mercaptoacetamide (A14/B35) in 10 mM 
HEPES pH 7.5 at 22.5°C (chapter A) to 50 mM Tris pH 7.2 at 37°C (chapter B) shows differences 
in thiocarbamate half-lives with 26.8 ± 1.4 min for A7 at 22.5°C and 3.7 ± 0.1 min for B17 at 37°C. 
The faster activation in Tris buffer is most likely caused by the difference in temperature. 
Considering the human body temperature of 37°C, the rapid activation in Tris buffer is presumably 
closer to a scenario of potential application in men. Certainly, thiocarbamate stability was not 
determined in human plasma, so differences in half-life cannot be excluded. Still, in terms of 
temperature and pH our assay conditions are close to the physiological state. Consequently, it can 
be assumed that the thiocarbamate function would be completely hydrolyzed after the prodrug was, 
for instance, exposed to human plasma after intravenous application. This would prevent reduced 
activity due to incomplete prodrug activation. Thiols like captopril were shown to form disulfides 
not only in aqueous systems;198 in fact this is also possible for the dry substance as in a tablet.199 
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Hence, stability of the undissolved compound, which eventually affects shelf life, will also be 
enhanced by using this thiocarbamate protection group. 
4.3 Changing the ‘Warhead’ to a Hydroxamic Acid 
 
Several thiol-containing drugs are in clinical use, as for example the aforementioned antiplatelet 
drug clopidogrel,194 the antidiarrheal racecadotril195 or the ACE inhibitor captopril.200 A drawback 
of thiols is their sensitivity to oxidation to the respective disulphides.198 Consequently, newer ACE 
inhibitors like enalapril do not contain sulfhydryl groups and are less prone to oxidative 
metabolism.201 As an alternative to the use of a thiocarbamate prodrug to avoid oxidation, the 
strategy of replacing the thiol ‘warhead’ was pursued in chapter C.  
Among the newly synthesized compounds derived from lead thiol B36, which included several 
carboxylic acids (C3-C6) and an alcoholic isoster C8, hydroxamic acid C7 is the only one with in 
vitro activity on LasB (IC50 17.4 ± 0.8 µM). This indicates that in combination with the 
phenylacetamide core a strong zinc binder is necessary for protease inhibition. 
Even though B36 and C7 differ only by the zinc-chelating group, remarkable differences in their 
binding to LasB were found. In the past, the presence of inhibitors at the active site of LasB was 
related to a closure of the active site cleft due to hinge-bending motion.202 Concrete examples for 
this phenomenon include a peptidic inhibitor203 and phosphoramidon.204 We also made this 
observation for hydroxamate C7. By contrast, the open conformation of the apo protein is virtually 
maintained upon binding of thiol B36. An explanation for the different conformation of the enzyme 
when occupied by these inhibitors was provided by the respective binding modes: The perpetuation 
of the open conformation is most likely caused by the unexpected presence of two molecules of 
B36 in the protease. The second, antiparallelly oriented thiol does not chelate the active site zinc, 
but rather occupies the lipophilic S2´ pocket. It presumably prevents the protease from closing over 
the zinc-binding molecule, which therefore cannot undergo interactions with the edge strand. By 
contrast, only one molecule of hydroxamate C7 was found in the pocket. The absence of a second 
molecule enabled C7 to interact with the catalytic zinc and the edge strand alike, allowing the 
characteristic closure of the active site cleft. 
Apart from the conformation of the enzyme and the number of ligands bound, the orientation of the 
inhibitor backbone was not equivalent either for this new compound. While the amide oxygen of 
B36 is able to form a bidentate hydrogen bond with Arg198, the twisted orientation of the backbone 
of C7 does not allow this interaction anymore. The 2.5-fold weaker activity of the hydroxamate 
toward the thiol might be originated from the lack of this interaction. 
In all, these findings point out that replacement of the zinc-chelating group of a metalloprotease 
inhibitor, even if it does not cause a crucial difference in activity, can lead to substantial changes in 
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the binding mode. This does not only affect the orientation of the inhibitor in the pocket, but even 
the conformation of the entire protease. 
4.4 Selectivity toward Human MMPs 
 
As outlined in the introduction, a critical requirement for protease inhibitors is selectivity toward 
other protease anti-targets. For zinc-metalloproteases these are in particular human MMPs, due to 
their versatile functions (see chapter 1.6). For this reason, it was a key goal of this study to develop 
inhibitors selectively targeting bacterial proteases. Therefore, we analyzed the potential activity of 
selected compounds on MMPs. In order to cover a broad range of these antitargets, six 
representative enzymes with differing depth of the S1´ binding pocket were chosen, namely the 
following: MMP-1, -7 (shallow), MMP-2, -8 (intermediate) and MMP-3, -14 (deep). 
For the N-aryl mercaptoacetamides high selectivity was not necessarily to be expected, considering 
the presence of a common zinc anchor and their small size. However, the compounds displayed an 
unprecedented selectivity with negligible inhibition of all anti-targets tested. This could be 
attributed to the interactions with the non-primed edge strand in ColH. This structural element is 
also present in MMPs, but since it is tilted by 27-29°, productive interactions with the N-aryl 
mercaptoacetamides are not possible. In line with these results, selected inhibitors showed 
promising activities on collagenases from other Gram-positive species like C. tetani or B. cereus. 
Mimicking the zinc-coordination sphere in MMPs by mutation of the glutamate ligand in ColH to 
histidine did not cause a tremendous drop in activity, thus this interaction could be excluded as 
alternative selectivity determinant. 
The maintenance of the high selectivity of the thiols when changing the zinc-chelating group to a 
hydroxamate was equally surprising. This is especially true in view of the fact that the interactions 
of the hydroxamic acid function with LasB are highly similar to reported structures of hydroxamates 
in complex with MMP-7,205 MMP-3206 or with thermolysin,207 leading to a commonly observed 
distorted trigonal-bipyramidal coordination geometry.208 Consequently, the observed selectivity 
must be determined by the interactions of the backbone of the molecule. Comparing the orientation 
of the molecules in the binding pocket it becomes apparent that contrary to C7, the aforementioned 
inhibitors occupy the shallow (MMP-7) or deep (MMP-3) S1´ binding pocket of the respective 
targets. Interactions at this site of the MMPs have been discussed as a reason for poor selectivity of 
protease inhibitors.16,186 Accordingly, it appears likely that the observed inactivity of C7 toward all 
tested MMPs can be attributed to a lack of binding to this subsite. 
It remains to be said that the selectivity of the mercaptoacetamides was explained based on their 
interactions with the non-primed edge strand in ColH but not with regard to the complex with LasB. 
In this case, a primed binding mode was observed, which raises the question why this alternative 
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orientation of the inhibitor would not lead to MMP inhibition. Assuming absence of the second 
ligand in a hypothetical MMP-thiol complex, one could conclude that again the non-occupation of 
the S1´ pocket and the lack of edge strand interactions is the reason for the inactivity toward MMPs. 
Contrary to other studies about bacterial protease inhibitors (see chapter 1.4.3 and 1.5.3), which 
focused mostly on only a few antitargets, this work describes the N-aryl mercaptoacetamides to be 
selective toward a broad range of six MMPs. The selection of representative enzymes differing in 
the S1´ site might allow conclusions about the inhibition of other structurally related MMPs which 
were not tested. Presumably, the compounds described herein are also highly selective towards 
further MMPs because of the abovementioned non-occupation of the S1´ pocket and the inability 
to interact with the non-primed edge strand. 
Along with their low cytotoxicity of toward selected human cell lines, these results constitute an 
important prerequisite for the potential application of these protease inhibitors for the treatment of 
infections with Clostridia or P. aeruginosa. 
4.5 Biological Evaluation of the Impact of LasB Inhibition 
 
Having in hand inhibitors with promising in vitro activity on LasB, it was of high interest to analyze 
the impact of LasB inhibition by these compounds in more complex assay systems. To this end, the 
potential to restore the effect of the AMP LL-37 was investigated. Furthermore, effects on biofilm 
formation and on the biofilm component eDNA were analyzed. As outlined in the introduction, 
these effects represent important resistance mechanisms of P. aeruginosa. The most advanced assay 
performed in this study is an early in vivo infection model using G. mellonella. 
 
4.5.1 LL-37 Rescue 
LL-37 is a human α-helical cathelicidin peptide with antimicrobial activity against various bacteria, 
including P. aeruginosa.209 It contributes to the innate defense system and is upregulated in CF 
patients, with concentrations correlating to disease severity.210,211 Apart from its antimicrobial 
properties due to membrane permeabilization,209 LL-37 is known to inhibit the formation of 
P. aeruginosa biofilms and to destruct existing biofilms, exerting synergistic effects in combination 
with classical antibiotics.212–214 This is caused partly by QS-mediated downregulation of several 
genes, e.g. lasB.213 Schmidtchen et al. reported proteases from various bacterial species, including 
P. aeruginosa LasB, to degrade LL-37 for the purpose of immune evasion.118 These findings and 
the fact that LL-37 cleavage can be prevented with ilomastat118 prompted us to analyze the impact 
of our hydroxamate-based inhibitor on this immune evasive process. 
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As described in chapter C, we found only a weak effect of LL-37 on the growth of PA14 
at 25 µg/mL. This is in line with reported MIC values towards P. aeruginosa strains of 
>32 µg/mL.212–214 In order to exclude growth inhibition by C7, its potential antibacterial properties 
were investigated, revealing only a weak effect at high concentrations (p < 0.05 at 250 µM). 
Remarkably, bacterial growth was significantly decreased in a concentration-dependent manner 
when PA14 cultures supplemented with LL-37 were treated with hydroxamate C7. This 
demonstrates that LasB inhibition has the potential to restore the innate defense system of the host 
which is otherwise impaired by P. aeruginosa. Hence, in an infectious disease state, apart from the 
reduced invasiveness caused by LasB inhibition, the rescue of LL-37 could be of additional benefit 
for the patient, because of the recovered antimicrobial activity and its anti-biofilm effect.212,213 
 
4.5.2 Effects on Biofilm Formation and eDNA Release 
As mentioned earlier, the biofilm is a central element favoring resistance of P. aeruginosa whose 
formation is also dependent on LasB.121,122 Inhibition of LasB has been demonstrated to lead to 
reduced biofilm formation.128 Thus, it was of great interest whether on top of strengthening the host, 
hydroxamate C7 could also further weaken P. aeruginosa by interfering with a key resistance 
mechanism.  
The assay revealed a dose-dependent reduction of the total biofilm volume by C7. In addition to 
that, a significant effect on the release of the major biofilm component eDNA was observed. As 
discussed above, we found a direct effect of C7 on the activity of LL-37. Indirectly, the reduction 
of eDNA should boost the activity of this AMP as well, as it is known to lead to resistance toward 
LL-37.71 Similarly, the biofilm reduction could lead to an increased activity of conventional 
antibiotics.69,72,215 In case of β-lactams, this could further be achieved by direct inhibition of metallo-
β-lactamases.216,217 In vitro activity on IMP-7, an enzyme of this class isolated from clinical strains 
of P. aeruginosa, by thiol inhibitor B36 is an encouraging first result toward the end of an additional 
restoration effect on penicillin and related antibiotics.  
 
4.5.3 In Vivo Efficacy in Galleria mellonella 
The G. mellonella infection experiment is a potent in vivo model, with substantial advantages over 
murine models in terms of expenses, required instruments and ethical constraints.218 For 
P. aeruginosa, pathogenicity has been shown to highly correlate with mouse models.219 In the 
Hartmann group, this model has been employed to demonstrate in vivo efficacy of PqsR inhibitors83 
and dual inhibitors of PqsR and PqsD.215  
P. aeruginosa has been reported to produce LasB after infection of G. mellonella.220 The protease 
itself is toxic for the larvae and stimulates an immune response at concentrations below the lethal 
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dosis.221 LasB has further been discussed to evade the G. mellonella immune response by degrading 
antimicrobial peptides of the insect.222 
The in vivo effect of LasB inhibition by thiol B36 and its prodrug B27 was investigated. To this 
end, larvae were challenged with a bacterial load corresponding to two CFUs, which is two times 
the LD50 determined by Jander et al.219 As pointed out in chapter B, the survival rate of the larvae 
was increased significantly from 43% for the untreated larvae to 72% for larvae receiving 2.5 nmol 
of B36. The ineffectiveness of prodrug B27 could be due to insufficient activation in the 
G. mellonella hemolymph. In vivo efficacy of structurally related LasB inhibitors has been proven 
by Zhu et al. using a Caenorhabditis elegans model.132 The lifetime of the worms was significantly 
prolonged when treated with the LasB inhibitors, however, contrary to our results, the overall 
survival was not affected.132 Hence, in our assay, inhibition of the virulence factor LasB did not 
only decelerate disease progression, but importantly reduced the pathogenicity so much so that less 
larvae were killed. 
 
Taken together, these biological results highlight how the in vitro activity of our LasB inhibitors 
could be translated into significant effects in more complex systems. Using cellular assays, we were 
able to demonstrate reduction of biofilm formation and eDNA release, as well as a restoration effect 
on the activity of the AMP LL-37. Finally, we proved in vivo efficacy for a thiol inhibitor in Galleria 
mellonella. These findings reflect the various implications of LasB in the pathogenicity of 
P. aeruginosa (chapter 1.4.2) and clearly underline the potential of this extracellular protease as a 
drug target toward the development of novel, urgently needed anti-infectives. 
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4.6 Outlook 
 
The results described in this work regarding the potent and selective broad-spectrum inhibition of 
secreted bacterial collagenases pave the way for the rational and straightforward development of 
new antibacterial drugs with novel modes of action. 
Potential further steps in these projects include the following: 
 
- Further analysis of the inhibition of clostridial collagenases other than ColH, including 
dose-dependent measurements. 
- Analysis of the impact of collagenase inhibition on the cleavage of the natural substrate 
collagen. 
- Establishment of an in vivo model using Clostridium strains expressing the targeted 
proteases to assess the impact of collagenase inhibition in a more advanced setting. 
- Structure-based optimization of the inhibitors based on the here presented X-ray 
co-crystals. This could aim at (i) replacement of the bridging water molecule between ColH 
and A13 to increase affinity; (ii) development of a thiol inhibitor of LasB capable of leading 
to a closure of the active site cleft by engaging in more interactions with the binding site; 
(iii) replacement of the zinc-binding group of the thiols by alternative (e.g. heterocyclic) 
zinc chelators 
- Extension of the chemical space of LasB/ColH inhibitors by screening alternative 
compound libraries. 
- Analysis of the impact of LasB inhibition on the activity of antibiotics or LL-37 in biofilm 
or eDNA assays. 
- Determination of selected pharmacokinetic properties to obtain further information 
regarding a potential application in humans. This would be followed by additional 
modification of the compounds toward e.g. increased absorption or reduced metabolism 
when necessary. 
- Extension of the selectivity tests to further metalloproteases like HDAC or ACE. 
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